Purchase this article with an account.
Ahmed A I Sallam, Javier Zarranz-Ventura, Quresh Mohamed, Robert Johnston, ; United Kingdom national database study of intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion related macular oedema. Patients’ pre-treatment characteristics and treatment procedure. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3913.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To describe patients’ demographics, ocular co-pathology and treatment procedures for patients receiving Ozurdex for macular oedema due to branch and central retinal vein occlusion in the UK National Health Service (NHS)
A multicenter national database study of prospectively collected anonymized data within an electronic medical record system (Medisoft®). Data from participating NHS centres across the UK were automatically extracted. For this report we analyzed data from 5 of these centres. Pre-treatment characteristics assessed included: patients’ age, gender, race and co-existing ocular pathology. Data pertaining to injection episodes were also examined
This study included 602 eyes of 567 patients receiving a total of 1162 intravitreal Ozurdex injections. Mean age of patients at the time of first injection was 70.8 years and 51% (289) of patients were females. 57% (323) were Caucasians, 3 % were Asians and in 40% (227), patients’ race was not known. Of all pre-existing ocular co-morbidities, age related macular degeneration was the commonest (16.8% %) while diabetic retinopathy accounted for 5.3% and glaucoma/ocular hypertension for 3.7%. Most Ozurdex injections were performed under topical anaesthesia (64.7%) with subconjunctival anaesthesia being used in 15.6%, subtenon anaesthesia in 4.8% and peri/retrobulbar in 0.9%. Most injections were administered in the inferior temporal quadrant (78.6%), followed by superior temporal (20.3%), inferior nasal (0.6%) and superior nasal quadrant (0.5%). 42.2% of all in injections were performed by consultants, 43.3% by independent non-consultants and 14.5% by trainees. Intraoperative complications were only reported in 4.2% of all administered injections, the commonest being subconjunctival haemorrhage (33%) and ocular pain (5.2%). Corneal abrasion was reported in 3.5% and vitreous haemorrhage was recorded in only 1.8%. There was no record of lens injury
Knowledge of disease associated co-morbidities and rate of operative complications of treatments has implications on service planning and delivery. Ozurdex is administered through a 22-gauge needle; however, this does not appear to be associated with significant operative complications or pain. Use of Ozurdex in patients with glaucoma is feasible but caution is required
This PDF is available to Subscribers Only